Bleselumab - Astellas Pharma/Kyowa Hakko Kirin

Drug Profile

Bleselumab - Astellas Pharma/Kyowa Hakko Kirin

Alternative Names: 4D11; ASKP 1240

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; Kyowa Hakko Kirin
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Focal segmental glomerulosclerosis; Renal transplant rejection
  • No development reported Transplant rejection
  • Discontinued Plaque psoriasis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Transplant-rejection(In volunteers) in USA (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Transplant-rejection(Prevention) in Japan (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top